StemCell Institute (7096) AI Stock Analysis

Compare

0 Followers

Top Page

StemCell Institute

(7096)

Rating:75Outperform

Price Target:―

The overall score for StemCell Institute is driven by strong financial performance, notably in revenue and net income growth, and a robust balance sheet. However, the variability in cash flow and high valuation temper the overall outlook. Technical indicators suggest a stable price trend but caution due to potential overbought conditions. The absence of recent earnings call insights or significant corporate events leaves these areas neutral in the evaluation.

StemCell Institute (7096) vs. iShares MSCI Japan ETF (EWJ)

Market Cap

¥12.23B

Dividend YieldN/A

Average Volume (3M)17.51K

Price to Earnings (P/E)31.4

Beta (1Y)0.52

Revenue Growth10.00%

EPS Growth41.04%

CountryJP

Employees98

SectorHealthcare

Sector Strength43

IndustryBiotechnology

Share Statistics

EPS (TTM)4.49

Shares Outstanding10,246,600

10 Day Avg. Volume39,390

30 Day Avg. Volume17,510

Financial Highlights & Ratios

PEG Ratio-5.30

Price to Book (P/B)5.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

StemCell Institute Business Overview & Revenue Model

Company DescriptionStemCell Institute (7096) is a biotechnology company specializing in the research and development of stem cell therapies. The company operates in the healthcare sector, focusing on the advancement of regenerative medicine. Its core services include providing clinical-grade stem cell products for therapeutic applications, conducting clinical trials, and offering consulting services in stem cell research and therapy development.

How the Company Makes MoneyStemCell Institute makes money through several key revenue streams. The company generates income by selling clinical-grade stem cell products to healthcare providers and research institutions. Additionally, it earns revenue by conducting clinical trials and licensing its proprietary technologies to pharmaceutical companies. The company may also form strategic partnerships with other biotech firms to co-develop stem cell therapies, sharing both costs and profits. Consulting services in the field of stem cell research and development further contribute to its earnings.

StemCell Institute Financial Statement Overview

Summary

StemCell Institute presents a strong financial profile with impressive growth and profitability metrics, particularly in revenue and net income growth. The balance sheet is solid with low leverage and strong equity utilization. However, cash flow management appears less stable, suggesting a need for better cash flow strategies to ensure consistent operational support.

Income Statement

Very Positive

StemCell Institute demonstrates robust revenue growth and profitability. The Gross Profit Margin stands at 62.95% for TTM, reflecting efficient cost management. Net Profit Margin is a healthy 14.98%, indicating strong bottom-line performance. Revenue Growth Rate from previous year is 29.98%, showcasing effective expansion strategies. EBIT and EBITDA Margins are 15.76% and 19.22% respectively, underscoring operational efficiency.

Balance Sheet

Very Positive

The company maintains a solid financial position with a low Debt-to-Equity Ratio of 0.15, indicating low financial leverage. Return on Equity is impressive at 14.76%, highlighting effective use of shareholders’ equity. The Equity Ratio of 37.27% suggests a stable capital structure, though there is room for improving asset efficiency.

Cash Flow

Positive

Cash flow management shows potential for improvement. The Free Cash Flow to Net Income Ratio is unavailable due to zero cash flow, reflecting potential operational cash constraints. Historical cash flow data indicates variability, with a need for more consistent cash flow generation to support sustainable growth.

TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Breakdown
Income Statement		Total Revenue
2.64B	2.48B	2.09B	1.78B	1.41B	1.68B
	Gross Profit
1.66B	1.58B	1.34B	1.11B	924.21M	1.13B
	EBIT
415.52M	413.76M	297.56M	226.95M	86.88M	383.00M
	EBITDA
506.52M	534.00M	383.89M	309.47M	119.66M	-1.00M
	Net Income Common Stockholders
395.00M	310.98M	198.03M	133.73M	62.37M	277.00M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
3.53B	2.85B	3.32B	3.51B	2.74B	3.02B
	Total Assets
7.18B	6.54B	5.81B	5.22B	3.96B	3.56B
	Total Debt
399.00M	8.78M	5.89M	0.00	0.00	0.00
	Net Debt
-3.13B	-2.84B	-3.32B	-3.51B	-2.74B	-3.02B
	Total Liabilities
4.50B	3.85B	3.51B	3.11B	2.64B	2.30B
	Stockholders Equity
2.68B	2.69B	2.30B	2.10B	1.32B	1.26B
Cash Flow		Free Cash Flow
0.00	132.97M	39.77M	264.81M	-164.34M	602.84M
	Operating Cash Flow
0.00	334.63M	99.67M	469.29M	239.00M	667.86M
	Investing Cash Flow
0.00	-811.77M	-285.10M	404.17M	-520.26M	-108.01M
	Financing Cash Flow
0.00	-1.33M	-869.00K	644.37M	0.00	0.00

StemCell Institute Technical Analysis

Technical Analysis Sentiment

Negative

Last Price1183.00

Price Trends

50DMA

1308.58

Negative

100DMA

1331.49

Negative

200DMA

1474.08

Negative

Market Momentum

MACD

-34.15

Positive

RSI

38.06

Neutral

STOCH

12.70

Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7096, the sentiment is Negative. The current price of 1183 is below the 20-day moving average (MA) of 1269.90, below the 50-day MA of 1308.58, and below the 200-day MA of 1474.08, indicating a bearish trend. The MACD of -34.15 indicates Positive momentum. The RSI at 38.06 is Neutral, neither overbought nor oversold. The STOCH value of 12.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7096.

StemCell Institute Peers Comparison

Overall Rating

UnderperformOutperform

Sector (52)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7096	75 Outperform	¥12.23B	31.40		―	10.00%	41.04%
4578	72 Outperform	$3.56T	10.20	13.46%	1.69%	14.52%	156.70%
4587	70 Outperform	$233.04B	15.08	29.98%	―	66.89%	506.88%
Sector *	52 Neutral	$5.19B	3.04	-44.20%	2.82%	16.59%	-0.39%
4593	49 Neutral	¥36.73B	―		―	374.19%	35.53%
4565	48 Neutral	$74.02B	―	-3.36%	―	87.83%	75.84%
4592	48 Neutral	¥215.25B	―	-123.63%	―	―	-3.32%

* Healthcare Sector Average

Performance Comparison

JP:7096

StemCell Institute

1,174.00

-539.70

-31.49%

JP:4593

Healios KK

359.00

222.00

162.04%

JP:4578

Otsuka Holdings Co

6,631.00

499.27

8.14%

JP:4565

Sosei Group

802.00

-638.00

-44.31%

JP:4587

Peptidream

1,718.50

-165.50

-8.78%

JP:4592

SanBio Co

3,475.00

2,998.00

628.51%

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.